Circio and Lonza Sign Research Agreement to Test Circular mRNA Tech

Circio Holding ASA, a Norway-based biotech innovator, announced a new research evaluation agreement between its Swedish subsidiary Circio AB and global CDMO leader Lonza. The partnership allows Circio to assess its proprietary circVec circular mRNA expression technology using Lonza’s advanced transient protein expression platform—marking a key step toward scaling next-gen mRNA therapeutics.

The collaboration gives Circio access to Lonza’s expertise in protein production as it continues developing cutting-edge circular mRNA tools for nucleic acid-based medicine. According to the company, further updates will be provided as the evaluation progresses, potentially paving the way for deeper collaboration in therapeutic manufacturing.